dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Desai, Jayesh |
dc.contributor.author | Alonso-Casal, Guzman |
dc.contributor.author | Kim, Se Hyun |
dc.contributor.author | Cervantes, Andrés |
dc.contributor.author | Karasic, Thomas |
dc.contributor.author | MEDINA RODRIGUEZ, LAURA |
dc.date.accessioned | 2024-02-01T11:30:39Z |
dc.date.available | 2024-02-01T11:30:39Z |
dc.date.issued | 2024-01 |
dc.identifier.citation | Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30:271–8. |
dc.identifier.issn | 1078-8956 |
dc.identifier.uri | https://hdl.handle.net/11351/10949 |
dc.description | Divarasib; Càncer colorectal; Desenvolupament de medicaments |
dc.description.sponsorship | This study was sponsored by Genentech. We thank the patients and family members that were involved in this trial, as well as the clinical study teams. Writing assistance was provided by A. Occiano and S. Diaz of Genentech. |
dc.language.iso | eng |
dc.publisher | Nature Portfolio |
dc.relation.ispartofseries | Nature Medicine;30 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Anomalies cromosòmiques |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | Recte - Càncer - Tractament |
dc.subject.mesh | Mutation |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41591-023-02696-8 |
dc.subject.decs | mutación |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1038/s41591-023-02696-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Desai J] Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. [Alonso G] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Kim SH] Seoul National University Bundang Hospital, Seongnam, South Korea. [Cervantes A] Hospital Clinico Universitario De Valencia, Valencia, Spain. [Karasic T] Abramson Cancer Center, University Of Pennsylvania, Philadelphia, PA, USA. [Medina L] Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain |
dc.identifier.pmid | 38052910 |
dc.identifier.wos | 001116421800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |